Renaissance Technologies
ESLA icon

Renaissance Technologies’s Estrella Immunopharma ESLA Stock Holding History

Renaissance Technologies’s Portfolio ESLA Stock Details ESLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$66.6K Sell
62,795
-59,673
-49% -$68.6K ﹤0.01% 3081
2025
Q4 		$191K Buy
122,468
+111,779
+1,046% +$212K ﹤0.01% 2895
2025
Q3 		$12.3K Buy
+10,689
New +$10.3K ﹤0.01% 3446

Other funds holding ESLA

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Renaissance Technologies's ESLA Position: Q1 2026 in Review

Renaissance Technologies reduced its Estrella Immunopharma (ESLA) stake by 49% in Q1 2026, selling an estimated $68.6K and leaving 62,795 shares worth $66.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3081.

Renaissance Technologies first reported a position in ESLA in Q3 2025 and has held it in 3 quarters since. The position peaked at $191K in Q4 2025. 16 funds tracked by Wall St. Rank hold ESLA as of Q1 2026.

  • Renaissance Technologies held 62,795 shares of Estrella Immunopharma worth $66.6K as of Q1 2026.
  • Renaissance Technologies sold 59,673 Estrella Immunopharma shares in Q1 2026, an estimated $68.6K.
  • Estrella Immunopharma made up ﹤0.01% of Renaissance Technologies's portfolio in Q1 2026, its #3081 holding.
  • Renaissance Technologies first reported a position in Estrella Immunopharma in Q3 2025 and has held it in 3 quarters since.
  • Renaissance Technologies's Estrella Immunopharma position peaked at $191K in Q4 2025.
  • 16 funds tracked by Wall St. Rank held Estrella Immunopharma as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.